Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | GJB2 | P29033 | 2/20 | 0.34 |
| ▸ | HRAS | P01112 | 1/20 | 0.34 |
| ▸ | YWHAZ | P63104 | 2/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10831460 | 1.00 | L3MBTL1 (0.39) | L3MBTL1TACR1TMEM97SIGMAR1MEN1 | |
| SCHEMBL7154934 | 0.90 | MEN1 (0.41) | L3MBTL1TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL15890505 | 0.82 | L3MBTL1 (0.40) | L3MBTL1TMEM97SIGMAR1HRASGSTP1 | |
| SCHEMBL5308210 | 0.82 | L3MBTL1 (0.54) | L3MBTL1TMEM97SIGMAR1KMT2AHRAS | |
| SCHEMBL1836110 | 0.82 | L3MBTL1 (0.54) | L3MBTL1TMEM97SIGMAR1KMT2AHRAS | |
| SCHEMBL16153926 | 0.82 | SLC6A2 (0.47) | SLC6A2GJB2HRAS | |
| SCHEMBL10832391 | 0.81 | L3MBTL1 (0.41) | L3MBTL1TACR1TMEM97SIGMAR1MEN1 | |
| SCHEMBL13953444 | 0.81 | MEN1 (0.39) | L3MBTL1TACR1TMEM97SIGMAR1MEN1 | |
| SCHEMBL8720842 | 0.81 | MEN1 (0.39) | L3MBTL1TACR1TMEM97SIGMAR1MEN1 | |
| SCHEMBL15012280 | 0.80 | L3MBTL1 (0.46) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0224260-A2 | Analogs of nonreducing monosaccharide moiety of lipid A | Toho Yakuhin Kogyo Kabushiki Kaisha (JP) | 1987-06-03 | — | — | EP | claimed |
| JP-62129292-A | — | — | None | — | — | JP | disclosed |
| JP-1213290-A | — | — | None | — | — | JP | disclosed |
| JP-63044588-A | — | — | None | — | — | JP | disclosed |
| EP-1105401-B1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORP (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | CORIXA CORPORATION | 2002-01-31 | — | — | US | disclosed |
| EP-1105401-A1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORPORATION (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011010-A1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORPORATION (US) | 2000-03-02 | — | — | WO | disclosed |
| US-6013640-A | ANTIISCHEMIC AGENTS | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| US-RE36385-E | TREATMENT OF TUMORS, ENHANCING IMMUNITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0288888-B1 | Novel glucopyranose derivatives | ONO PHARMACEUTICAL CO (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-4925929-A | ANTITUMOR AGENTS | ONO PHARMACEUTICAL CO. LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| JP-H01213290-A | NOVEL PHOSPHORYL GLUCOSAMINE DERIVATIVE | TOHO YAKUHIN KOGYO KK | 1989-08-28 | — | — | JP | disclosed |
| EP-0288888-A2 | Novel glucopyranose derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-11-02 | — | — | EP | disclosed |
| US-4746742-A | IMMUNOLOGY, ANTI-TUMOR | TOHO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1988-05-24 | — | — | US | disclosed |
| JP-S6344588-A | LACTASE-TYPE ISOMER OF LIPID A MONOSACCHARIDE ANALOG | TOHO YAKUHIN KOGYO KK | 1988-02-25 | — | — | JP | disclosed |
| JP-S62129292-A | LIPID A MONOSACCHARIDE RELATED SUBSTANCE DEVELOPING BIOLOGICAL ACTIVITY | TOHO YAKUHIN KOGYO KK | 1987-06-11 | — | — | JP | disclosed |
| EP-0224260-A2 | Analogs of nonreducing monosaccharide moiety of lipid A | Toho Yakuhin Kogyo Kabushiki Kaisha (JP) | 1987-06-03 | — | — | EP | disclosed |
| EP-0188697-A2 | 2-deoxy-4-0-phosphoryl-2-[(3'-0-tetradecanoyl)-tetradecanoylamino]-3-0-tetradecanoyl-D-glucose and stereoisomers thereof | Toho Yakuhin Kogyo Kabushiki Kaisha (JP) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | PYGL, GPI, PNLIP | L3MBTL1 635/4885TACR1 2840/4885TMEM97 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.